Alterity Therapeutics (ATHE) Net Cash Flow (2016 - 2020)

Alterity Therapeutics has reported Net Cash Flow for 5 years, with the latest figure at -$6.2 million in Q2 2020.

• For the quarter ending Q2 2020, Net Cash Flow rose 36.76% year-over-year to -$6.2 million; the trailing twelve-month figure through Dec 2021 stood at -$6.2 million (up 64.8% YoY), and the FY2025 full-year result was $13.3 million, up 692.99% from the prior year.
• Net Cash Flow for Q2 2020 stood at -$6.2 million, down from -$1.6 million in the prior quarter.
• The five-year high for Net Cash Flow was -$47278.4 in Q2 2018, with the low at -$9.8 million in Q2 2019.
• Average Net Cash Flow over 5 years is -$3.8 million, with a median of -$4.4 million recorded in 2017.
• Year-over-year, Net Cash Flow soared 98.93% in 2018 and plunged 20575.33% in 2019.
• Tracing ATHE's Net Cash Flow over 5 years: stood at -$598231.8 in 2016, then tumbled by 56.04% to -$933486.7 in 2017, then slumped by 444.27% to -$5.1 million in 2018, then surged by 68.41% to -$1.6 million in 2019, then sank by 285.17% to -$6.2 million in 2020.
• The last three Net Cash Flow figures came in at -$6.2 million (Q2 2020), -$1.6 million (Q4 2019), and -$9.8 million (Q2 2019), per Business Quant data.

Peer Comparison